BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 27309985)

  • 1. Extrafine beclometasone diproprionate/formoterol fumarate: a review of its effects in chronic obstructive pulmonary disease.
    Singh D; Corradi M; Spinola M; Petruzzelli S; Papi A
    NPJ Prim Care Respir Med; 2016 Jun; 26():16030. PubMed ID: 27309985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhaled beclometasone dipropionate/formoterol fumarate extrafine fixed combination for the treatment of asthma.
    Crisafulli E; Zanini A; Pisi G; Pignatti P; Poli G; Scuri M; Chetta A
    Expert Rev Respir Med; 2016; 10(5):481-90. PubMed ID: 26938578
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of single-inhaler extrafine triple therapy versus inhaled corticosteroid plus long-acting beta2 agonist in eastern Asian patients with COPD: the TRIVERSYTI randomised controlled trial.
    Zheng J; Baldi S; Zhao L; Li H; Lee KH; Singh D; Papi A; Grapin F; Guasconi A; Georges G
    Respir Res; 2021 Mar; 22(1):90. PubMed ID: 33757520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single inhaler triple therapy with extrafine beclomethasone, formoterol, and glycopyrronium for the treatment of chronic obstructive pulmonary disease.
    Singh D
    Expert Opin Pharmacother; 2018 Aug; 19(11):1279-1287. PubMed ID: 29985096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment response according to small airways disease status: The effects of high-strength extrafine pMDI beclomethasone dipropionate/formoterol fumarate in fixed dose combination in moderate uncontrolled asthmatic patients.
    Carpagnano GE; Scioscia G; Lacedonia D; Stornelli SR; Irene Quarato CM; Soccio P; Resta O; Foschino Barbaro MP
    Pulm Pharmacol Ther; 2020 Feb; 60():101879. PubMed ID: 31866498
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of inhaled extrafine beclometasone dipropionate/formoterol fumarate/glycopyrronium bromide on distal and central airway indices, assessed using Functional Respiratory Imaging in COPD (DARWiIN).
    Skloot GS; Guasconi A; Lavon BR; Georges G; De Backer W; Galkin D; Cortellini M; Panni I; Bates JHT
    Respir Res; 2023 Oct; 24(1):244. PubMed ID: 37803368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Airway Deposition of Extrafine Inhaled Triple Therapy in Patients with COPD: A Model Approach Based on Functional Respiratory Imaging Computer Simulations.
    Usmani OS; Scichilone N; Mignot B; Belmans D; Van Holsbeke C; De Backer J; De Maria R; Cuoghi E; Topole E; Georges G
    Int J Chron Obstruct Pulmon Dis; 2020; 15():2433-2440. PubMed ID: 33116458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial.
    Papi A; Vestbo J; Fabbri L; Corradi M; Prunier H; Cohuet G; Guasconi A; Montagna I; Vezzoli S; Petruzzelli S; Scuri M; Roche N; Singh D
    Lancet; 2018 Mar; 391(10125):1076-1084. PubMed ID: 29429593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and pharmacodynamics of an extrafine fixed pMDI combination of beclometasone dipropionate/formoterol fumarate in adolescent asthma.
    Kuna P; Govoni M; Lucci G; Scuri M; Acerbi D; Stelmach I
    Br J Clin Pharmacol; 2015 Sep; 80(3):569-80. PubMed ID: 25808292
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lung Deposition of the Dry Powder Fixed Combination Beclometasone Dipropionate Plus Formoterol Fumarate Using NEXThaler
    Virchow JC; Poli G; Herpich C; Kietzig C; Ehlich H; Braeutigam D; Sommerer K; Häussermann S; Mariotti F
    J Aerosol Med Pulm Drug Deliv; 2018 Oct; 31(5):269-280. PubMed ID: 29989511
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Triple therapy in COPD: new evidence with the extrafine fixed combination of beclomethasone dipropionate, formoterol fumarate, and glycopyrronium bromide.
    Singh D; Corradi M; Spinola M; Papi A; Usmani OS; Scuri M; Petruzzelli S; Vestbo J
    Int J Chron Obstruct Pulmon Dis; 2017; 12():2917-2928. PubMed ID: 29062229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The bronchodilator effects of extrafine glycopyrronium added to combination treatment with beclometasone dipropionate plus formoterol in COPD: A randomised crossover study (the TRIDENT study).
    Singh D; Schröder-Babo W; Cohuet G; Muraro A; Bonnet-Gonod F; Petruzzelli S; Hoffmann M; Siergiejko Z;
    Respir Med; 2016 May; 114():84-90. PubMed ID: 27109816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small airway inflammation and extrafine inhaled corticosteroids plus long-acting beta
    Pirina P; Foschino Barbaro MP; Paleari D; Spanevello A
    Respir Med; 2018 Oct; 143():74-81. PubMed ID: 30261996
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute cardiovascular safety of two formulations of beclometasone dipropionate/formoterol fumarate in COPD patients: A single-dose, randomised, placebo-controlled crossover study.
    Singh D; Ciurlia G; Piccinno A; Muraro A; Bocchi M; Scuri M
    Pulm Pharmacol Ther; 2017 Feb; 42():43-51. PubMed ID: 28065679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effects of extrafine beclometasone/formoterol (BDP/F) on lung function, dyspnea, hyperinflation, and airway geometry in COPD patients: novel insight using functional respiratory imaging.
    De Backer J; Vos W; Vinchurkar S; Van Holsbeke C; Poli G; Claes R; Salgado R; De Backer W
    J Aerosol Med Pulm Drug Deliv; 2015 Apr; 28(2):88-99. PubMed ID: 25004168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials.
    Virchow JC; Kuna P; Paggiaro P; Papi A; Singh D; Corre S; Zuccaro F; Vele A; Kots M; Georges G; Petruzzelli S; Canonica GW
    Lancet; 2019 Nov; 394(10210):1737-1749. PubMed ID: 31582314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The efficacy of extrafine beclomethasone dipropionate-formoterol fumarate in COPD patients who are not "frequent exacerbators": a post hoc analysis of the FORWARD study.
    Singh D; Vezzoli S; Petruzzelli S; Papi A
    Int J Chron Obstruct Pulmon Dis; 2017; 12():3263-3271. PubMed ID: 29138555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extrafine HFA-beclomethasone-formoterol vs. nonextrafine combination of an inhaled corticosteroid and a long acting β2-agonist in patients with persistent asthma: A systematic review and meta-analysis.
    Liu T; Yang D; Liu C
    PLoS One; 2021; 16(9):e0257075. PubMed ID: 34478483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Extrafine Beclometasone Dipropionate/Formoterol Fumarate vs Double Bronchodilation Therapy in Patients with COPD: A Historical Real-World Non-Inferiority Study.
    Voorham J; Baldi S; Santoro L; Kerkhof M; Contoli M; Fabbri LM; Kerstjens HAM; Luis López-Campos J; Roche N; Singh D; Vogelmeier CF; Price DB
    Int J Chron Obstruct Pulmon Dis; 2020; 15():2739-2750. PubMed ID: 33149571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ceiling effect of beclomethasone/formoterol/glycopyrronium triple fixed-dose combination in COPD: A translational bench-to-bedside study.
    Rogliani P; Ora J; Girolami A; Rossi I; de Guido I; Facciolo F; Cazzola M; Calzetta L
    Pulm Pharmacol Ther; 2021 Aug; 69():102050. PubMed ID: 34129945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.